ABBOTT INDIA LIMITED

LogicFlo AI raised $2.7 million in seed funding led by Lightspeed to expand its AI agent platform across pharmaceutical, biotech, and medtech organizations globally.

Beta Bionics announced plans to integrate its iLet Bionic Pancreas automated insulin delivery system with Abbott's future dual glucose-ketone sensor in the U.S.

Abbott and MSD Pharmaceuticals have formed a strategic distribution partnership to expand access to MSD's oral anti-diabetic portfolio in India, including sitagliptin and its fixed-dose combinations.

Abbott received FDA approval for the Tendyne transcatheter mitral valve replacement system, marking the first device of its kind to replace mitral valves without open-heart surgery for patients with severe mitral annular calcification.

Abbott's FreeStyle Libre continuous glucose monitoring system is the first CGM shown to reduce cardiovascular complication severity in diabetes patients, with data showing a 78% reduction in heart-related hospitalizations for Type 1 diabetes patients.

The critical limb ischemia (CLI) market is expected to grow from $1.4 billion in 2024 to $2.5 billion by 2035, with a CAGR of 6.66%, fueled by advances in early detection technologies and personalized medicine approaches.

Avadel Pharmaceuticals has appointed Susan Rodriguez as Chief Operating Officer to lead commercial strategy and operations for LUMRYZ, the first once-at-bedtime oxybate treatment for narcolepsy.

The global diabetes care market is expected to grow from $34.51 billion in 2025 to $62.73 billion by 2032, representing a compound annual growth rate of 8.9%.

Atrasentan, an ETA receptor antagonist originally developed by Abbott in the 1990s for prostate cancer, has received FDA accelerated approval in 2025 for IgA nephropathy (IgAN).

Abbott has established a groundbreaking agreement to integrate data from its FreeStyle Libre continuous glucose monitoring systems directly into Epic's electronic health records, benefiting over 280 million U.S. patients.